C-reactive protein and cardiovascular disease: Weighing the evidence

被引：68

作者：

Lowe G.D.O. ^{[1
]}

Pepys M.B. ^{[1
]}

机构：

[1] Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, University College London, London NW3 2PF, Rowland Hill Street

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 5期

基金：

英国医学研究理事会; 英国惠康基金; 美国国家卫生研究院;

关键词：

Arterioscler Thromb Vasc Biol; Coronary Heart Disease Event; Mendelian Randomization; Incident Coronary Heart Disease; Mendelian Randomization Study;

D O I：

10.1007/s11883-006-0040-x

中图分类号：

学科分类号：

摘要：

C-reactive protein (CRP) has been widely promoted as a strong, independent predictor of cardiovascular events and metabolic syndrome, both in general populations and in patients with clinical cardiovascular disease, and as a causal player in atherothrombosis. However, recent evidence shows that the association of CRP with cardiovascular events is weaker than previously thought, that it may be largely attributed to confounding by established causal risk factors, and that CRP is, therefore, probably not a clinically useful risk predictor. The lack of association of non-coding CRP gene polymorphisms (which determine different baseline CRP values) with coronary events or metabolic syndrome does not support a causal role for CRP, and most of the putatively proatherothrombotic in vitro effects claimed for CRP were caused by contaminants in commercial CRP preparations and not by CRP. Future clinical trials of specific CRP inhibitors now in development could directly test the contribution of CRP to pathogenesis of cardiovascular disease. Copyright © 2006 by Current Science Inc.

引用

页码：421 / 428

页数：7

共 50 条

[1]

Pepys M.B., Hirschfield G.M., C-reactive protein: A critical update, J Clin Invest, 111, pp. 1805-1812, (2003)

[2]

Suleiman M., Khatib R., Agmon Y., Et al., Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: Predictive role of C-reactive protein, J Am Coll Cardiol, 47, pp. 962-968, (2006)

[3]

Ridker P.M., Cushman M., Stampfer M.J., Et al., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 336, pp. 973-979, (1997)

[4]

Ridker P.M., Rifai N., Rose L., Et al., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, 347, pp. 1557-1565, (2002)

[5]

Danesh J., Whincup P., Walker M., Et al., Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses, BMJ, 321, pp. 199-204, (2000)

[6]

Ridker P.M., Clinical application of C-reactive protein for cardiovascular disease detection and prevention, Circulation, 107, pp. 363-369, (2003)

[7]

Ridker P.M., Cardiology Patient Page. C-reactive protein. A simple test to predict risk of heart attack and stroke, Circulation, 108, (2003)

[8]

Pearson T.A., Mensah G.A., Alexander R.W., Et al., Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, 107, pp. 499-511, (2003)

[9]

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, Eur J Cardiovasc Prev Rehabil, 10, SUPPL. 1, (2003)

[10]

Pepys M.B., CRP or not CRP? That is the question, Arterioscler Thromb Vasc Biol, 25, pp. 1091-1094, (2005)

← 1 2 3 4 5 →